Lundbeck has stopped development of its investigational stroke drug desmoteplase following disappointing results from its Phase III studies. The DIAS-3 …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

